
Laurie Menger
@lauriemengerlab
INSERM tenured scientist
ATIP-avenir Institut Gustave Roussy U1015
In vivo genome-wide CRISPR screens for T-cell therapies Lab
ID: 1202911133969133568
06-12-2019 11:22:31
140 Tweet
363 Followers
310 Following

Fantastic meeting on Cell Therapy in Paris, May 2024! Justin Eyquem Belkaid Lab @realFlorentGinhoux Katy Rezvani, M.D., Ph.D @MarsonLab Majzner_Lab Julie Helft Alena Gros @amigorena Roychoudhuri Lab Luca Gattinoni Claire Roddie Suman MITRA Laurie Menger @CecileAlanio @MichelSadelain

Join us! We seek a highly motivated lab/research manager to join a friendly and dynamic team and contribute to new therapy development in immune regulation and cancer immunosuppression Roychoudhuri Lab @CamPathology CRUKCambridge. Deadline 28 Feb, Apply: jobs.cam.ac.uk/job/44969/


New paper🚨12 cases mucorales post-CAR-T. Devastating mould infection. HUGE mortality.Key to improved survival?AWARENESS & EARLY combined surgery+antifungal +reversal risk factors Kathleen Cheok Neil Stone The Lancet Infectious Diseases sciencedirect.com/science/articl…


📅Next ImmunoPasteur seminar this Thursday David Raulet from UC Berkeley Regulation of immune function and repertoire: the example of natural killer cells Invited by Bousso Lab


IMPROVING ADOPTIVE CELL THERAPY Deadline for abstract submission at : April 2, 2024 Please submit your abstract to the following address: [email protected]




Huge thanks to all speakers and participants of the "Improving Adoptive cell Therapy" conference in Paris last week.@realFlorentGinhoux Julie Helft Majzner_Lab @MarsonLab Roychoudhuri Lab Justin Eyquem Claire Roddie


Dunsmore et al. used inducible tdTomato monocyte labeling to probe the emergence of tumor-associated macrophage (TAM) subsets enriched in mouse PDAC. bit.ly/4dwaL6d Garett Dunsmore @realFlorentGinhoux




We are hiring a postdoc to work on T cell engineering and chromatin modifiers!!please send application to [email protected]


Our lab is also hiring a COMPUTATIONAL Scientist to explore transcriptomic epitranscriptomic and epigenetic landscape of our T cell therapies (CAR, TILs). Please send CV and ref [email protected]



Very proud and excited to share our recent study from Silvia Menegatti identifying FAS as a target outperfoming B2M in allogeneic CART resistance to T and NK cell mediated lysis! Nature Biomedical Engineering Institut Curie Gustave Roussy nature.com/articles/s4155…

Many congratulations to Claire Roddie et al for this amazing work. Obe-cel (recently FDA approved for replaced B-ALL) has demonstrated impressive responses and safety profile in a very challenging disease nejm.org/doi/full/10.10…


For a collaborative project with @realFlorentGinhoux, we are seeking a highly motivated postdoctoral fellow for developing combinatorial CAR therapies in pediatric cancers!


Thank you for the positive feedback on our article Nature Biomedical Engineering nature.com/articles/s4155…